A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea

LEO Pharma

Status: Completed

Conditions: Rosacea

Treatments: Drug: Azelaic Acid (Finacea Foam, BAY39-6251)

Study type: Observational

Funder types: Industry

Identifiers

NCT03193372

19638

Details and patient eligibility

About

To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment

Enrollment: 2,200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age
• Diagnosis of rosacea by a medical professional
• Currently using Finacea Foam as topical monotherapy for rosacea
• Willing and able to provide voluntary, informed consent to participate in this study

Exclusion criteria

• Use of any other topical treatment for rosacea at the time of enrollment

Trial design

2,200 participants in 1 patient group

Rosacea Concierge Program

Description:

Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam

Treatment:

Drug: Azelaic Acid (Finacea Foam, BAY39-6251)